Lyell Immunopharma

$6.04 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Lyell Immunopharma

Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Stock Analysis

last close $6.04
1-mo return -38%
3-mo return -55.3%
avg daily vol. 934.56T
52-week high 19.84
52-week low 5.83
market cap. $1.5B
forward pe -
annual div. -
roe -
ltg forecast -7.9%
dividend yield -
annual rev. $9M
inst own. 32.2%
baraka

Subscribe now for daily local and international financial news

Subscribe